Biotech Startups

Curileum develops regenerative medicine therapies targeting intestinal stem cells to prevent colorectal cancer. The company works with specialist partners in chemistry and regulatory affairs to advance its clinical pipeline.

1 investor

Curiosis is a biotech company focusing on bio-pharmaceutical supply chain components and materials. The company operates in the medical device and biotechnology sector in South Korea.

1 investor

Curis is a biopharmaceutical company focused on drug development and clinical advancement. The company's board includes experienced leaders in oncology, immunology, dermatology, and pharmaceutical development.

1 investor

Curtana Pharmaceuticals develops small molecule drugs targeting cancer stem cells in brain tumors, specifically gliomas and related CNS malignancies. The company focuses on OLIG2 inhibition to overcome treatment resistance and recurrence in pediatric and adult brain cancers.

1 investor

Curve builds BIOBRIC, a modular production system for precision fermentation and cell cultivation designed to reduce the capital and operating costs of biomanufacturing for lower-margin industries such as food, cosmetics, materials, and functional ingredients. It combines hardware with data simulations for strain and process optimization, and licenses validated setups to producers scaling commercial protein and bioidentical ingredient production.

1 investor

CV6 Therapeutics develops investigational cancer therapies designed for combination use with established standards of care, with a lead program (CV6-168) intended to enhance the activity of 5-fluorouracil and other thymidylate synthase-targeted therapies. The company is advancing CV6-168 through Phase 1a clinical development.

1 investor

CyanoCapture develops a synthetic biology platform using genetically engineered photosynthetic cells that convert CO2 into high-value molecules such as enzymes, growth factors, peptides, bioplastics, and drug compounds. The company targets biomanufacturing and critical supply chain applications through a zero-sugar, CO2-based production process.

1 investor

Cyanomin develops a biological desalination process that uses bacteria with electrically charged biofilms to adsorb and remove ions from hypersaline brines, treating wastewater without membranes, pressure, or heat. It serves industries that generate hypersaline wastewater, including oil & gas, lithium and copper extraction, and seawater desalination.

1 investor

Cybele Microbiome studies how skincare ingredients affect the skin microbiome and its postbiotic output, using that knowledge in clinical trials to develop products with better efficacy and fewer side effects. It focuses on the link between ingredients, the microbiome, and human skin health.

1 investor

Bio Green Med Solution is a diversified company operating in fire protection and biopharmaceutical sectors, with headquarters in Malaysia and a portfolio spanning pharmaceutical R&D and fire protection products and services.

1 investor

Cyclarity Therapeutics develops drugs based on cyclodextrin derivatives to treat atherosclerosis by removing arterial plaque, targeting the non-degradable cholesterol that accumulates in arterial wall cells. The company aims to provide a preventive therapy for age-related cardiovascular conditions such as heart attack and stroke.

1 investor

Cycle0 is a vertically integrated developer, investor, builder, and operator of biomethane plants across Europe that converts waste into renewable natural gas to reduce carbon emissions. The company serves agriculture, waste, food, and water sector organizations seeking renewable energy solutions and emissions reductions.

1 investor

Cyclerion is a biopharmaceutical company developing therapeutics for neuropsychiatric diseases, with a lead candidate (CYC-126) for treatment-resistant depression that pairs anesthetic agents with a personalized biofeedback-driven device. It targets patients, providers, and health systems seeking individualized mental health treatment.

1 investor

Cyclicor is a biotechnology company based in Lund, Sweden that develops sustainable alternatives for plastics and coatings. The company focuses on transitioning the chemical industry toward circular economy solutions.

1 investor

Cyclotek manufactures and distributes PET radiopharmaceuticals and radioactive medical devices for hospitals, research institutions, and clinical partners across Australia and New Zealand. The company provides GMP manufacturing, supply chain coordination, and translational support to enable molecular imaging diagnostics and therapy.

1 investor

Captisol is a pharmaceutical-grade sulfobutylether beta-cyclodextrin (SBECD), a derivatized beta cyclodextrin used to solubilize and stabilize difficult-to-deliver molecules across routes such as parenteral, oral, ophthalmic, nasal, and inhalation. Made by CyDex Pharmaceuticals (a Ligand company), it is used in approved therapeutics including remdesivir and carfilzomib, and is also explored for consumer health, supplements, and personal care products.

1 investor

CyGenica develops a targeted intracellular drug delivery technology, the GEENIE platform, to deliver therapeutic molecules into cells more safely and efficiently. Its work focuses on treatments for oncology and rare genetic diseases, serving biopharmaceutical companies developing therapies.

1 investor

Cynapsus is a specialty central nervous system pharmaceutical company developing a fast-acting, sublingual thin film for on-demand management of OFF episodes in Parkinson's disease patients. It is preparing to commercialize the therapy.

1 investor

CynosBio develops and commercializes regenerative medicine products, including cell-based treatments for cartilage damage, joint disorders, and liver disease. The company is based in Japan and pursues global expansion, particularly in the United States.

1 investor

Cyrano Therapeutics is a clinical-stage regenerative medicine company developing CYR-064, a nasal therapy for post-viral smell loss (hyposmia) and associated loss of taste. It serves patients with anosmia and is advancing its lead candidate through clinical trials toward Phase 3.

1 investor

cystetic Medicines is a drug development company creating an inhaled dry-powder therapy based on an FDA-approved antifungal compound to treat cystic fibrosis, targeting the roughly 10% of patients not helped by existing modulators. The company focuses on accessible, scalable treatment using aerodynamically engineered nanoparticle delivery.

1 investor

Cyta Therapeutics develops polymer-based nanogel therapeutics (IntelliGels) to treat obesity, NASH, type 2 diabetes, and metabolic disorders. The company's lead program, Cyta-001, is a liver-targeted drug delivery system encapsulating a thyroid hormone receptor agonist for metabolic disease management.

1 investor

CytoAgents is a clinical-stage biopharmaceutical company developing therapies for the life-threatening symptoms of Cytokine Release Syndrome (CRS), an immune overreaction causing systemic inflammation. It is led by a team of drug development experts and a scientific advisory board focused on immunology and clinical drug development.

1 investor

1 investor